Download PDF
Horm Metab Res 2021; 53(04): 219-224
DOI: 10.1055/a-1392-0938
Review

Polycystic Ovary Syndrome and Fibrocystic Breast Disease: An Updated Review

Michał Kunicki
1   Department of Gynecological Endocrinology, Medical University of Warsaw, Warsaw, Poland
2   Invicta Private Fertility Center, Warsaw, Poland
,
Roman Smolarczyk
1   Department of Gynecological Endocrinology, Medical University of Warsaw, Warsaw, Poland
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints

Abstract

Polycystic ovary syndrome (PCOS) is the most common hormonal disorder in women of reproductive age. There is no clear association between PCOS and benign breast disease (BBD). The latter is a frequent benign disorder, affecting women between 20 and 50 years of age. To date, the classification remains controversial, and the risk of developing breast cancer that is associated with these changes is different depending on the histopathological findings. The most frequent changes are breast cysts, which are noted in up to 50% of patients older than 30 years of age. This up-to-date review presents the relationship between PCOS and BBD. In conclusion, there is no clear association between benign breast disease and PCOS. Further studies on a large population with prospectively collected data using updated PCOS criteria are necessary.

Key words

polycystic ovarian syndrome - benign breast disease - fibrocystic breast changes - obesity - insulin resistance

Supplementary Material



Publication History

Received: 25 May 2020

Accepted: 07 February 2021

Article published online:
08 March 2021

© 2021. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Teede HJ. Recommendations from the international evi- dence-based guideline for the assessment and management of polycystic ovary syndrome. Hum Reprod 2018; 33: 1602-1618 Erratum: Hum Reprod 2019; 34: 388
    CrossrefPubMedGoogle Scholar
  • 2 Escobar-Morreale HF. Polycystic ovary syndrome: Definition, aetiology, diagnosis and treatment. Nat Rev Endocrinol 2018; 14: 270-284
    CrossrefPubMedGoogle Scholar
  • 3 Dumesic DA, Oberfield SE, Stener-Victorin E. etal. Scientific statement on the diagnostic criteria, epidemiology, pathophysiology, and molecular genetics of polycystic ovary syndrome. Endocr Rev 2015; 36: 487-525
    CrossrefPubMedGoogle Scholar
  • 4 Moran LJ, Norman RJ, Teede HJ. Metabolic risk in PCOS: Phenotype and adiposity impact. Trends Endocrinol Metab 2015; 26: 136-143
    CrossrefPubMedGoogle Scholar
  • 5 Rotterdam ESHRE/ASRM-Sponosored PCOS Consensus Work shop Group (2004) Revised 2003 consensus on diagnostic cri teria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004; 19: 41-47
    CrossrefPubMedGoogle Scholar
  • 6 Lefebvre P, Raingeard I, Renard E. et al. Long-term risks of polycysticovaries syndrome. Gynecol Obstet Fertil 2004; 32: 193-198
    CrossrefPubMedGoogle Scholar
  • 7 Welt CK, Gundmudsson JA, Aranon G. et al. Characterizing discrete subsets of polycystic ovary syndrome as defined by the Rotterdam criteria: the impact of weight on phenotype and metabolic features. J Clin Endocrinol Metab 2006; 41: 4842-4848
    CrossrefPubMedGoogle Scholar
  • 8 Carmina E, Wong L, Chang L. et al. Endocrine abnormalities in ovulatory women with polycystic ovaries on ultrasound. Hum Reprod 1997; 12: 905-909
    CrossrefPubMedGoogle Scholar
  • 9 Iftikhar S, Collazo-Clavell ML, Roger VL. et al. Risk of cardiovascular events in patients with polycystic ovary syndrome. Neth J Med 2012; 70: 74-80
    PubMedGoogle Scholar
  • 10 Legro RS, Gnatuk CL, Kunselman AR. et al. Changes in glucose tolerance over time in women with polycystic ovary syndrome: A controlled study. J Clin Endocrinol Metab 2005; 90: 3236-3242
    CrossrefPubMedGoogle Scholar
  • 11 Moran LJ, Misso ML, Wild RA. et al. Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update 2010; 16: 347-363
    CrossrefPubMedGoogle Scholar
  • 12 Diamanti-Kandarakis E, Kouli C, Alexandraki K. et al. Failure of mathematical indices to accurately assess insulin resistance in lean, overweight, or obese women with polycystic ovary syndrome. J Clinl Endocrinol Metab 2004; 89: 1273-1276
    CrossrefPubMedGoogle Scholar
  • 13 Pasquali R, Gambineri A, Pagotto U. The impact of obesity on reproduction in women with polycystic ovary syndrome. BJOG 2006; 113: 1148-1159
    CrossrefPubMedGoogle Scholar
  • 14 Fisher SA, Reid RL, Van Vugt DA. et al. A random- ized double-blind comparison of the effects of clomiphene citrate and the aromatase inhibitor letrozole on ovulatory function in normal women. Fertil Steril 2002; 78: 280-285
    CrossrefPubMedGoogle Scholar
  • 15 Dunaif A. Insulin resistance in women with polycystic ovary syndrome. Fertil Steril 2006; 86: S13-S14
    CrossrefPubMedGoogle Scholar
  • 16 Book CB, Dunaif A. Selective insulin resistance in the polycystic ovary syndrome. J Clin Endocrinol Metab 1999; 84: 3110-3116
    PubMedGoogle Scholar
  • 17 Gadalla MA, Norman RJ, Tay CT. al. Medical and surgical treatment of reproductive outcomes in polycystic ovary syndrome: An overview of systematic reviews. Int J Fertil Steril 2020; 4: 257-270
    PubMedGoogle Scholar
  • 18 Joham AE, Palomba S. et al. Polycystic ovary syndrome, obesity, and pregnancy. Semin Reprod Med 2016; 34: 93-101
    Article in Thieme ConnectPubMedGoogle Scholar
  • 19 Palomba S, de Wilde MA, Falbo A. et al. Pregnancy complications in women with polycystic ovary syndrome. Hum Reprod Update 2015; 21: 575-592
    CrossrefPubMedGoogle Scholar
  • 20 Walters KA, Gilchrist RB, Ledger WL. et al. New perspectives on the pathogenesis of PCOS: Neuroendocrine origins. Trends Endocrinol Metab 2018; 29: 841-852
    CrossrefPubMedGoogle Scholar
  • 21 Paris VR, Bertoldo MJ. The Mechanism of Androgen Actions in PCOS Etiology. J Med Sci (Basel) 2019; 7: 89
    PubMedGoogle Scholar
  • 22 Livadas S, Pappas C, Karachalios A. et al. Prevalence and impact of hyperandrogenemia in 1,218 women with polycystic ovary syndrome. Endocrine 2014; 47: 631-638
    CrossrefPubMedGoogle Scholar
  • 23 Rosenfield RL, Ehrmann DA. The Pathogenesis of Polycystic Ovary Syndrome (PCOS): The Hypothesis of PCOS as Functional Ovarian Hyperandrogenism Revisited. Endocr Rev 2016; 5: 467–520.
    PubMed
  • 24 Keefe CC, Goldman MM, Zhang K. et al. Simultaneous measurement of thirteen steroid hormones in women with polycystic ovary syndrome and control women using liquid chromatography-tandem mass spec-trometry. PLoS One 2014; 9: e93805
    CrossrefPubMedGoogle Scholar
  • 25 Sullivan, S.D. and Moenter, S.M Prenatal androgens alter GABAergic drive to gonadotropin-releasing hormone neurons: implications for a common fertility disorder. Proc Natl Acad Sci U. S. A. 2004; 101: 7129–7134
    PubMed
  • 26 Herbison AE, Moenter SM. Depolarising and hyper- polarising actions of GABA(A) receptor activation on gonadotrophin-releasing hormone neurones: Towards an emerging consensus. J. Neuroendocrinol 2011; 23: 557-569
    CrossrefPubMedGoogle Scholar
  • 27 Wang T, Han S, Tian W. et al. Effects of kisspeptin on pathogenesis and energy metabolism in polycystic ovarian syndrome (PCOS). Gynecol Endocrinol 2019; 35 9 807-881
    CrossrefPubMedGoogle Scholar
  • 28 Wang F, Niu WB, Kong HJ. et al. The role of AMH and its receptor SNP in the pathogenesis of PCOS. Mol Cell Endocrinol 2017; 439: 363-368
    CrossrefPubMedGoogle Scholar
  • 29 Filippou P, Homburg R. Is foetal hyperexposure to androgens a cause of PCOS?. Hum Reprod Update 2017; 23: 421-432
    CrossrefPubMedGoogle Scholar
  • 30 Hughes LE, Mansel RE, Webster DJT. Benign disorders and diseases of the breast—concepts and clinical management. 2nd Ed.. London: W. B. Saunders; 2000: 123-135
    Google Scholar
  • 31 Dupont WD, Page DL. Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med 1985; 312: 146-151
    CrossrefPubMedGoogle Scholar
  • 32 Courtillot C, Plu-Bureau NBinart. et al. Benign breast diseases. J Mammary Gland Biol Neoplasia 2005; 10: 325-335
    CrossrefPubMedGoogle Scholar
  • 33 Goehring C, Morabia A. Epidemiology of benign breast disease, with special attention to histologic types. Epidemiol Rev 1997; 19: 310-327
    CrossrefPubMedGoogle Scholar
  • 34 Guray M, Sahin A. Benign breast Disease: Classification, Diagnosis and Management. Oncologist 2006; 11: 435-449
    CrossrefPubMedGoogle Scholar
  • 35 Stachs A, Stubert J, Reimer T. et al. Benign Breast Disease in Women. Dtsch Arztebl Int 2019; 116: 565-574
    PubMedGoogle Scholar
  • 36 Marchant DJ. Benign breast disease. Obstet Gynecol Clin North Am 2002; 29: 1-20
    CrossrefPubMedGoogle Scholar
  • 37 Santen RJ, Mansel R. Benign breast disorders. N Engl J Med 2005; 353: 275-285
    CrossrefPubMedGoogle Scholar
  • 38 Collins LC, Aroner SA, Connolly JL. et al. Breast cancer risk by extent and type of atypical hyperplasia: An update from the Nurses’ Health Studies. Cancer 2016; 122: 515-520
    CrossrefPubMedGoogle Scholar
  • 39 Hislop TG, Elwood JM. Risk factors for benign breast disease: A 30-year cohort study. Can Med Assoc J 1980; 124: 283-291
    PubMedGoogle Scholar
  • 40 Fiorica JV. Fibrocystic changes. Obstet Gynecol clin North Am 1994; 21: 445-485
    CrossrefPubMedGoogle Scholar
  • 41 Sitruk- Ware LR, Stenkers N, Mowszowicz I. et al. Inadequate corpus luteal function in women with benign breast disease. J Clin Endocrinol Metab 1977; 44: 771-774
    CrossrefPubMedGoogle Scholar
  • 42 Ayers JWT, Gidwani GP. The “Luteal breast” hormonal and sonographic investigation of benign breast disease in patients with cyclic mastalgia. Fertili Steril 1983; 40: 779-784
    CrossrefPubMedGoogle Scholar
  • 43 Burrows C, Holly JM, Laurence NJ. et al. Insulin-like growth factor binding protein 3 has opposing actions on malignant and nonmalignant breast epithelial cells that are each reversible and dependent upon cholesterol-stabilized integrin receptor complexes. Endocrinology 2006; 147: 3484-3500
    CrossrefPubMedGoogle Scholar
  • 44 Rohan TE, Cook MG, Potter JD. et al. A case-control study of diet and benign proliferative epithelial disorders of the breasts. Cancer Res 1990; 50: 3176-3181
    PubMedGoogle Scholar
  • 45 Hislop TG, Band PR, Deschamps M. et al. Diet and histologic types of benign breast disease definied by subsequent risk of breast cancer. Am J Epidemiol 1990; 131: 263-270
    CrossrefPubMedGoogle Scholar
  • 46 Ingram DM, Nottage E, Roberts T. The role of diet in the development of breast cancer: a case-control study of patients with breast cancer, benign epithelial hyperplasia and fibrocystic disease of breasts. Br J Cancer 1991; 64: 187-191
    CrossrefPubMedGoogle Scholar
  • 47 Parazzini F, Ferraroni M, La Vecchia C. et al. Smoking habits and risk of benign breast disease. Int J Epidemiol 1991; 20: 430-434
    CrossrefPubMedGoogle Scholar
  • 48 Parazzini F, La Vecchia C, Franceschi S. et al. Risk factors for pathologically confirmed benign breast disease. Am J Epidemiol 1984; 120: 115-122
    CrossrefPubMedGoogle Scholar
  • 49 Santen RJ. In: Benign Breast Disease in Women. Feingold KR, Anawalt B, Boyce A. et al. (eds). Endotext [Internet] South Dartmouth (MA): MDText.com, Inc.;
    Google Scholar
  • 50 Samoli E, Trichopoulos DA, Lagiou A. et al. The hormonal profile of benign breast disease. Br J Cancer 2013; 108: 199-204
    CrossrefPubMedGoogle Scholar
  • 51 Katz E, Adashi EY. Hyperprolactinemic disorders. Clin Obstet Ginecol 1990; 33: 622-639
    CrossrefPubMedGoogle Scholar
  • 52 Branchini G, Schneider L, Cericatto R. et al. Progesterone receptors A and B and estrogen receptor alpha expression in normal breast tissue and fibroadenomas. Endocrine 2009; 35: 459-466
    CrossrefPubMedGoogle Scholar
  • 53 Brkić M, Vujović S, Ivović M. et al. The role of E2/P ratio in the etiology of fibrocystic breast disease, mastalgia and mastodynia. Acta Clin Croat 2018; 57: 756-761
    PubMedGoogle Scholar
  • 54 Mady EA. Association between estradiol, estrogen receptors, total lipids, triglycerides, and cholesterol in patients with benign and malignant breast tumors. J Steroid Biochem Mol Biol 2000; 75: 323-328
    CrossrefPubMedGoogle Scholar
  • 55 Carvalho MJ, Subtil S, Rodrigues Â. et al. Controversial association between polycystic ovary syndrome and breast cancer. Eur J Obstet Gynecol Reprod Biol 2019; 243: 125-132
    CrossrefPubMedGoogle Scholar
  • 56 Dimitrakakis C, Bondy C. Androgens and the breast. Breast Cancer Res 2009; 11: 212 DOI: 10.1186/bcr2413. Review
    CrossrefPubMedGoogle Scholar
  • 57 Noroozzadeh M, Behboudi-Gandevani S, Mosaffa N. et al. High prevalence of benign mammary tumors in a rat model of polycystic ovary syndrome during postmenopausal period. Gynecol Endocrinol 2019; 358: 679-684
    CrossrefPubMedGoogle Scholar
  • 58 Carlstroem K, Doeberl A, Gershagen S. et al. Elevated peripheral levels of androgens and of some steroid sensitive plasma proteins in patients with severe fibrocystic breast disease: a preliminary report. Acta Obstet Gynecol Scand Suppl 1984; 63: 157-158
    CrossrefPubMedGoogle Scholar
  • 59 Wang DY, Fentiman IS. Epidemiology and endocrinology of benign breast disease. Breast Cancer Res Treat 1985; 6: 5-36
    CrossrefPubMedGoogle Scholar
  • 60 Delcour C, Robin G, Young J. et al. PCOS and Hyperprolactinemia: what do we know in 2019?. Clin Med Insights Reprod Health 2019; 13: 1179558119871921 DOI: 10.1177/1179558119871921. eCollection 2019, Review
    CrossrefPubMedGoogle Scholar
  • 61 Sieja K, Stanosz S. The concentrations of prolactin and estrogens in women with fibrocystic changes in the breast. Ginekol Pol 2002; 73: 594-599
    PubMedGoogle Scholar
  • 62 Peters F, Schuth W, Scheurich B. et al. Serum prolactin levels in patients with fibrocystic breast disease. Obstet Gynecol 1984; 64: 381-385
    PubMedGoogle Scholar
  • 63 Sitruk-Ware R, Clair F, Sterkers N. et al. Prolactin secretion in benign breast diseases. Gynecol Endocrinol 1987; 1: 195-200
    CrossrefPubMedGoogle Scholar
  • 64 Angelousi A, Diamanti-Kandarakis E, Zapanti E. et al. Is there an association between thyroid function abnormalities and breast cancer?. Arch Endocrinol Metab 2017; 61: 54-61
    CrossrefPubMedGoogle Scholar
  • 65 Gaberšček S, Zaletel K, Schwetz V. et al. Mechanisms in endocrinology: thyroid and polycystic ovary syndrome. Eur J Endocrinol 2015; 172: R9-R21
    CrossrefPubMedGoogle Scholar
  • 66 Chen YY, Fang WH, Wang CC. et al. Examining the Associations among Fibrocystic Breast Change, Total Lean Mass, and Percent Body Fat. Sci Rep 2018; 15: 9180
    CrossrefPubMedGoogle Scholar
  • 67 D’Amelio R, Farris M, Grande S. et al. Association between polycystic ovary and fbrocystic breast disease. Gynecol Obstet Invest 2001; 51: 134-137
    CrossrefPubMedGoogle Scholar
  • 68 Franks S. In: Morphology of the polycystic ovary. Dunaif A, Givens J. The Polycystic Ovary Syndrome. London: Blackwell Scientific Publications; 1992
    Google Scholar
  • 69 Dewailly D, Lujan ME, Carmina E. et al. Definition and significance of polycystic ovarian morphology: a task force report from the Androgen Excess and Polycystic Ovary Syndrome Society. Hum Reprod Update 2014; 20: 334-352
    CrossrefPubMedGoogle Scholar
  • 70 Gumus II, Koktener A, Dogan D. et al. Polycystic ovary syndrome and fibrocystic breast disease: is there any association?. Arch Gynecol Obstet 2009; 280: 249-253
    CrossrefPubMedGoogle Scholar
  • 71 Soran A, Talbott EO, Zborowski JV. et al. The prevalence of benign breast disease in women with polycystic ovary syndrome: a review of a 12-year follow-up. Int J Clin Pract 2005; 59: 795-797
    CrossrefPubMedGoogle Scholar
  • 72 Ozkaya E, Cakir E, Cinar M. et al. Is hyperandrogenemia protective for fibrocystic breast disease in PCOS?. Gynecol Endocrinol 2012; 8: 468-471
    CrossrefPubMedGoogle Scholar
  • 73 Brodell LA, Mercurio MG. Hirsutism: diagnosis and management. Gend Med 2010; 7: 79-87
    CrossrefPubMedGoogle Scholar
  • 74 Sarac ZF. Association between insulin resistance and breast parenchyma in women with polycystic ovary syndrome. Turk J Endocrinol Metab 2012; 16: 1-5
    CrossrefPubMedGoogle Scholar
  • 75 Eslami B, Alipour S, Hosseini R. et al. Breast density in polycystic ovarian syndrome patients: A case-control study. Int J Reprod Biomed (Yazd) 2019; 3: 577-584
    PubMedGoogle Scholar
  • 76 Rao AA, Feneis J, Lalonde C. et al. Pictorial Review of Changes in the BI-RADS Fifth Edition. Radiographics 2016; 36: 623-639
    CrossrefPubMedGoogle Scholar